Mostrar el registro sencillo del ítem

dc.contributor.author
Elgoyhen, Ana Belen  
dc.date.available
2023-10-25T15:54:15Z  
dc.date.issued
2023-06  
dc.identifier.citation
Elgoyhen, Ana Belen; The α9α10 nicotinic acetylcholine receptor: a compelling drug target for hearing loss?; Informa Healthcare; Expert Opinion On Therapeutic Targets; 26; 3; 6-2023; 291-302  
dc.identifier.issn
1472-8222  
dc.identifier.uri
http://hdl.handle.net/11336/215935  
dc.description.abstract
Introduction: Hearing loss is a major health problem, impacting education, communication, interpersonal relationships, and mental health. Drugs that prevent or restore hearing are lacking and hence novel drug targets are sought. There is the possibility of targeting the α9α10 nicotinic acetylcholine receptor (nAChR) in the prevention of noise-induced, hidden hearing loss and presbycusis. This receptor mediates synaptic transmission between medial olivocochlear efferent fibers and cochlear outer hair cells. This target is key since enhanced olivocochlear activity prevents noise-induced hearing loss and delays presbycusis. Areas covered: The work examines the α9α10 nicotinic acetylcholine receptor (nAChR), its role in noiseinduced, hidden hearing loss and presbycusis and the possibility of targeting. Data has been searched in Pubmed, the World Report on Hearing from the World Health Organization and the Global Burden of Disease Study 2019. Expert opinion: The design of positive allosteric modulators of α9α10 nAChRs is proposed because of the advantage of reinforcing the medial olivocochlear (MOC)-hair cell endogenous neurotransmission without directly stimulating the target receptors, therefore avoiding receptor desensitization and reduced efficacy. The time is right for the discovery and development of α9α10 nAChRs targeting agents and high throughput screening assays will support this.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Informa Healthcare  
dc.rights
info:eu-repo/semantics/restrictedAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
HEARING LOSS  
dc.subject
POSITIVE ALLOSTERIC MODULATORS  
dc.subject
PRESBYCUSIS  
dc.subject
TINNITUS  
dc.subject
Α9Α10 NICOTINIC RECEPTORS  
dc.subject.classification
Otorrinolaringología  
dc.subject.classification
Medicina Clínica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
The α9α10 nicotinic acetylcholine receptor: a compelling drug target for hearing loss?  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2023-10-25T10:07:06Z  
dc.journal.volume
26  
dc.journal.number
3  
dc.journal.pagination
291-302  
dc.journal.pais
Reino Unido  
dc.journal.ciudad
Londres  
dc.description.fil
Fil: Elgoyhen, Ana Belen. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina  
dc.journal.title
Expert Opinion On Therapeutic Targets  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1080/14728222.2022.2047931  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/14728222.2022.2047931